Welcome to BioLegend’s one-of-a-kind advanced search. Search by any one of the single fields below or narrow down your searches by using multiple parameters. Looking for an anti-mouse NK cell antibody for IHC? Or looking for a FITC-conjugated antibody against a human marker for dendritic cells to use for flow cytometry? Only BioLegend’s advanced search can provide you with the best answers. If you have further questions, please contact our technical service team at 858-768-5801.
Catalog Number
Specificity
GeneID
Clone
Format
Species Reactivity
Applications
Cell Type
Keywords
*To perform a multi-parameter search, be sure to click on "Match all fields" below:
Match all fields
Match any field
Exact match
Partial match
Use this document lookup tool to find Current Product Datasheets, Certificates of Analysis, or MSDS for any antibody products you have purchased from BioLegend.
Use the search box below to perform a site search of BioLegend.com powered by Google™.
Each lot of this antibody is quality control tested by ELISA assay. For ELISA capture applications, a concentration range of 4-8 µg/ml is recommended. To obtain a linear standard curve, serial dilutions of IL-10 recombinant protein ranging from 2000 to 15 pg/ml are recommended for each ELISA plate. It is recommended that the reagent be titrated for optimal performance for each application. * For ELISA capture, it is very critical to use 0.2 M Sodium Phosphate Buffer, pH 6.5 (11.8g Na2HPO4, 16.1g NaH2PO4; q.s. to 1.0 L) as coating buffer. Note: Carbonate buffer, pH 9.5 should not be used as coating buffer for JES5-2A5. It may cause high background and lower sensitivity.
COA:
Enter Lot#:
Application Notes:
ELISA or ELISPOT Capture1-5,7,10: The purified JES5-2A5 antibody is useful as the capture antibody in a sandwich ELISA or ELISPOT assay, when used in conjunction with the biotinylated JES5-16E3 antibody (Cat. No. 505004) as the detecting antibody. The LEAF™ purified antibody is suggested for ELISPOT capture.
Application References:
1. Sander, B., et al. 1993. J. Immunol. Meth. 166:201. 2. Abrams, J., et al. 1992. Immunol. Rev. 127:5. 3. Abrams, J. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20. 4. Mo, X., et al. 1995. J. Virol. 69:1288. 5. Sarawar, S., et al. 1994. J. Immunol. 153:1246. 6. Finkelman, F., et al. 2003. Curr. Prot. Immunol. John Wiley & Sons, New York. Unit 6.28. 7. Brummel, R. and Lenert, P., 2005. J. Immunol. 174:2429. 8. Hara, M., et al. 2001. J. Immunol. 166:3789. 9. Riemann, M., et al. 2005. J. Immunol. 175:3560.PubMed 10. Xu, G., et al. 2007. J. Immunol. 179:5358.PubMed 11. Koo, GC., et al. 2006. BMC Immunol. 18:7. PubMed
IL-10 was originally described as Cytokine Synthesis Inhibitory Factor (CSIF) by virtue of its ability to inhibit cytokine production by Th1 clones. IL-10 shares over 80% sequence homology with the Epstein-Barr virus protein BCRFI. The biological activities of IL-10 include inhibition of macrophage-mediated cytokine synthesis, suppression of the delayed type hypersensitivity response, and stimulation of the Th2 cell response, which results in elevated antibody production. The JES5-2A5 antibody reacts with mouse interleukin-10 (IL-10). The JES5-2A5 antibody can neutralize the bioactivity of natural or recombinant IL-10.
Other Names:
Interleukin-10, Cytokine synthesis inhibitory factor (CSIF), B cell derived T cell growth factor (B-TCGF), T cell growth inhibitory factor (TGIF)
Structure:
Acid-labile cytokine; dimer; 17-21 kD (Mammalian)
Regulation:
Downregulated by IL-4, IL-10
Cellular Sources:
Activated CD8+ T cells, TH0, TH2 subset of CD4+ T cells, Ly-1+ B cells, monocytes, macrophages, keratinocytes
Cellular Targets:
T cells, B cells, mast cells, macrophages
Receptors:
IL-10R (CDw210)
Bioactivity/Activities:
Inhibits IFN-γ, TNF-β, IL-2 production by TH1 clones; inhibits macrophage-mediated IL-1, IL-6, TNF-α synthesis; suppresses delayed type hypersensitivity response; stimulates TH2 cell response; mast cell proliferation
Antigen References:
1. Fitzgerald, K., et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego. 2. de Waal-Malefy, T, et al. 1992. Curr. Opin. Immunol. 4:314. 3. Howard, M., et al. 1992. Immunol. Today. 13:198. 4. Quesniaux, V. 1992. Research Immunol. 143:385.
*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/terms). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.
This data display is provided for general comparisons between formats. Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors. If you need assistance with selecting the best format contact our expert technical support team.